CTOs on the Move

Neighborhood Health Center of WNY

www.nhcwny.org

 
Impactful healthcare provided by kind people so Western New Yorkers can achieve their dreams and goals. Quality care, regardless of ability to pay. #unstoppable
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.nhcwny.org
  • 155, Lawn Avenue
    Buffalo, NY USA 14207
  • Phone: 716.332.3070

Executives

Name Title Contact Details
Megan Brophy
Director of Information Profile

Similar Companies

Louisiana Wholesale Drug Company

Louisiana Wholesale Drug Company is a Ruston, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator supporting customers from candidate selection to commercial launch.

Premier Research

Premier Research is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Astellas Pharma

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.

Black Diamond Therapeutics

Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery Engine in Basel, Switzerland.